Dutch-based medical device company ViCentra, which commercialises the Kaleido insulin patch pump system, has raised an additional $13 million as part of its Series D financing, with new capital coming from ROM Utrecht Region and a consortium of Dutch investors including Venturing Tech alongside increased support from existing investor Innovation Industries.
The $13 million top-up brings the Series D round to $98 million, following an $85 million raise in September 2025, and features participation from ROM Utrecht Region, a consortium of Dutch investors including Venturing Tech, and continued backing from Innovation Industries.
ViCentra, based in the Netherlands, develops and manufactures Kaleido, a compact and discreet alternative to traditional insulin pumps designed to support diabetes management. Kaleido is positioned as the smallest, lightest and most precise insulin patch pump in its class and delivers automated insulin therapy through integration with Diabeloop’s clinically validated hybrid closed-loop algorithms, DBLG1 and DBLG2.
Designed to resemble personal technology rather than a conventional medical device, Kaleido combines functionality with considered industrial design. It is constructed from premium materials and offers customizable aluminium shells in ten colour options, giving users flexibility in how and where the pump is worn while supporting everyday therapy management.
The company says the funding will be used to scale manufacturing capacity, strengthen commercial execution and customer support in Germany, the Netherlands and France, and accelerate preparations to bring its next-generation Kaleido system to the U.S. market, positioning ViCentra for continued growth in the insulin delivery sector.
